PerioChip® experts at the BDIA Dental Showcase 2015
The on-stand experts will be at this year’s BDIA Dental Showcase 2015, showing delegates why PerioChip® is a first line treatment for periodontal disease.
PerioChip® provides unique adjunctive treatment for periodontitis. After root surface debridement (RSD), PerioChip® is a reliable product to supplement your hard work by controlling bacteria and preventing infection without using antibiotics.
Designed for treating periodontal pockets >5mm, PerioChip® takes only 30 seconds to apply. Once placed, the chip immediately releases a high local concentration of chlorhexidine diglucontate, killing 99% of subgingival pathogenic bacteria over a seven to ten day period.[i] For further peace of mind the antimicrobial effects of PerioChip® continue to suppress bacterial flora for up to 11 weeks enabling the periodontium to stabilise and heal.[ii]
The BDIA Showcase is ideal opportunity to have a practical hands-on demonstration from the PerioChip® team and grab some valuable information to help your patients. Come and see us on stand D115.
To order PerioChip® or for further information Freephone 0800 013 2333 or email This email address is being protected from spambots. You need JavaScript enabled to view it.
[i] Jeffcoat M K et al. Adjunctive use of a subgingival controlled-release chlorhexidine chip. J Periodontal 1998; 69 (9): 989 – 997. http://www.ncbi.nlm.nih.gov/pubmed/9776027 [Accessed 26th May 2015]
[ii] Summary of Characteristics PerioChip® http://www.old.health.gov.il/units/pharmacy/trufot/alonim/PerioChip_dr_1337488974840.pdf [Accessed 26 May 2015]
About the author
Related Posts
Comments
By accepting you will be accessing a service provided by a third-party external to https://www.gdpuk.com/
GDPUK Ltd announces sale of intellectual property to leading publisher Cogora Group
GDPUK Ltd today announces the sale of its intellectual property assets to Cogora Group, one of the UK's leading publishers of healthcare brands, events and educational platforms.
The decision to sell GDPUK’s intellectual property forms part of a considered transition to ensure the long‑term stewardship and development of the brand and associated assets. Cogora brings a wealth of experience and expertise to support the continued evolution of the dentistry brand within its wide portfolio of market-leading healthcare publications. Its award-winning titles include Pulse, a long‑standing and widely recognised source of political news and clinical education for GPs, Nursing in Practice, Management in Practice, The Pharmacist, Pulse PCN and Healthcare Leader, as well as two secondary care publications – Hospital Healthcare Europe and Hospital Pharmacy Europe. The purchase will cement Cogora as the biggest publisher of primary care titles in the UK and allow it to bring its expertise in providing news, analysis, opinion and groundbreaking stories to GDPUK, as well as continue giving dentists and dental staff a voice through its website.
“After careful consideration, we believe that Cogora is well positioned to take GDPUK’s intellectual property forward,” said Tony Jacobs, founder, editor and publisher of GDPUK.com . “This transaction provides continuity for the professional community associated with GDPUK and creates opportunities for future growth under experienced ownership.”
Tony will continue involvement in GDPUK on a consulting basis.
GDPUK Ltd has worked to ensure an orderly transfer of the intellectual property and wishes Cogora every success in its future development.